Policy & Regulation
Ananda Pharma reports Phase 1 pharmacokinetic study results for MRX1
18 June 2026 - Ananda Pharma Limited, a UK pharmaceutical company developing regulatory approved cannabidiol medicines to treat complex, chronic conditions, announced on Wednesday the completion of it...
NMD Pharma reports further data from Phase 2a study of ignaseclant
18 June 2026 - NMD Pharma A/S, a Denmark-based clinical-stage biotechnology company, announced on Wednesday that further safety and efficacy data from its Phase 2a SYNAPSE-CMT exploratory study evalua...
Gesynta Pharma reports progress in Phase 2 trial of vipoglanstat
18 June 2026 - Swedish clinical-stage pharmaceutical company Gesynta Pharma AB announced on Wednesday that 50% of the target of 190 patients have been randomised in its Phase 2 clinical proof-of-conce...
Bayer completes acquisition of Perfuse Therapeutics to strengthen ophthalmology pipeline
17 June 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) confirmed on Wednesday that it has completed the acquisition of Perfuse Therapeutics Inc.Through this acq...
Akeso reports Phase II data for ligufalimab in AML
...
Optimi Health introduces standardised microdose psilocybin capsules for clinical research
17 June 2026 - Optimi Health Corp (NASDAQ:OPTH) (CSE:OPTI) (FSE:8BN0), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, announced on Tuesday that it has compl...